RankAlpha logo
Back to Rankings

CLYM

Climb BioB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Primary company sources support a genuinely catalyst-rich 2026: subcutaneous budoprutug data in H1 2026, initial CLYM116 healthy-volunteer data in mid-2026, and first budoprutug data from pMN, ITP, and SLE studies in H2 2026, while cash, cash equivalents, and marketable securities of $160.7 million at December 31, 2025 are expected to fund operations into 2028 [#PR-2026-03-05].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.1.
What can break
Clinical readouts in 2026 could miss on efficacy, PK/PD translation, or tolerability.
Momentum
97
Value
41
Sentiment
27
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $14.00 · Bear $5.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $11.43
Why
Momentum97 · Δ7d -1.1
Value41 · Δ7d +0.1
Sentiment27 · Δ7d -3.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
-1.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
27
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.0
Δ21d
+1.9
Why this grade

Composite grade B. Momentum 96.8 / Value 41.1 / Sentiment 27.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$675.67M
Beta
-0.15
Shares Out
68.18M
P/E (TTM) · Derived
-6.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-15.11
Rev YoY
-
EPS YoY
-42.8%
Gross Margin
-
Op Margin
-
Net Debt
-$150.92M
Current Ratio
18.38
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology